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Canine	B-cell	lymphoma	(BCL)	is	one	of	the	commonest	lymphoid	malignancies	in	dogs.	Conven0onally,	its	treatment	consists	
in	a	chemotherapy	protocol	but	new	therapies	are	emerging	such	as	immunotherapy.	It	consists	in	the	crea0on	of	an	immune	
response	against	malignant	B-cells	through	immunomodulatory	agents.		
Introduc)on	
ü  Inves0gate	if	monoclonal	an0bodies	for	human	B-cell	lymphoma	could	be	used	in	canine	B-cell	lymphoma.	
ü  To	do	research	on	speciﬁc	monoclonal	an0bodies	against	canine	B-cell	lymphoma.	
ü  To	review	the	vaccine-based	therapies	studied	in	human	NHL	and	more	extensively	in	canine	BCL.	
Objec)ves	
Monoclonal	An)bodies	(MAbs)	
Tumor	vaccines	
Plasmid	DNA	
Gene	sequence	
encoding	for	CD20	
CD20	expression	 An0bodies	against	CD20	
Ø  Rituximab	uniquely	binds	to	human	CD20.	
Ø  Mew	MAbs	speciﬁcally	targeted	against	canine	CD20,	such	as	
AT-004,	seem	a	promising	strategy	for	treatment	of	canine	B-
cell	lymphoma.	
Ø  Studies	with	Merial’s	DNA	vaccine	against	CD20	show	great	
eﬃcacy	but	further	studies	need	to	be	carried	out.		
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Figure	1.	Contrary	to	rituximab,	AT-004	binds	to	canine	CD20,	
speciﬁcally,	it	binds	to	large	extracellular	loop.	
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Merial	has	developed	a	xenogeneic	vaccine	containing	plasmid	DNA	which	encodes	for	CD20.	Consequently,	 it	enhances	the	
produc0on	of	an0bodies	against	CD20	and	crea0ng	a	long-term	destruc0on	of	malignant	B-cells	(Figure	3).		
Figure	3.	Mechanism	of	ac0on	of	plasmid	DNA	vaccine	against	canine	B-cell	lymphoma.	
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Rituximab	 is	 a	MAb	 against	 human	 CD20	 thus	 not	 binding	 to	 canine	
CD20.	 New	 therapeu0c	MAbs	 have	 been	 developed,	 such	 as	 AT-004	
(Aratana	 Therapeu0cs	 Inc.)	 which	 bind	 speciﬁcally	 to	 canine	 CD20	
(Figure	1).	Studies	show	longer	median	progression-free	survival	(PFS)	
and	 overall	 survival	 (OS)	 0mes	 in	 animals	 treated	 with	 an0-canine	
CD20	MAb	(Figure	2).	
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Figure	2.	Median	PFS	(A)	and	OS	(B)	0mes	in	animals	treated	
with	MAb	or	placebo	[1].	
